RQ Bio’s $157 Million Licence With AstraZeneca

Taylor Vinters advised RQ Bio on the deal.

RQ Bio emerges from stealth mode announcing its launch as a new UK-based biotechnology company following the completion of a successful licensing deal with AstraZeneca for RQ Bio’s existing mAbs against SARS-CoV-2.

Under the terms of the agreement, RQ Bio has granted AstraZeneca an exclusive worldwide licence to develop, manufacture and commercialise RQ Bio’s existing early stage mAbs against SARS-CoV-2 and a right of first refusal to take an exclusive licence in respect of any additional mAbs against SARS-CoV-2.

The Company, which is headquartered in London, is dedicated to developing treatments and preventative therapies based on potent broad-spectrum mAbs to provide instant and long-lasting immunity for vulnerable people at risk of severe disease or death from existing, emerging and new viral infections.

Taylor Vinters’ team included Patrick Farrant (Picture) and Maeve O’Hare.

Involved fees earner: Patrick Farrant – Taylor Vinters; Maeve O’Hare – Taylor Vinters;

Law Firms: Taylor Vinters;

Clients: RQ Bio;

Giulia Di Palma

Author: Giulia Di Palma